Brief: Helix Biopharma Corp signs non-binding letter of intent with Promab Biotechnologies to develop cell based therapies
22/12/2016 12:45
Dec 22 (Reuters) - Helix Biopharma Corp HBP.TO :
* Helix Biopharma Corp announces the signing of a
non-binding letter of intent with Promab Biotechnologies to
develop cell based therapies
* Helix Biopharma - LOI calls for both cos to complete a due
diligence and establish a collaboration to develop chimeric
antigen receptor t cell therapy
Source text for Eikon: ID:nMKW5wFpPa
Further company coverage: HBP.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020